5333.5000 32.00 (0.60%)
NSE Sep 05, 2025 15:31 PM
Volume: 237.7K
 

5333.50
0.60%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.
More from Alkem Laboratories Ltd.
Recommended